newsfilter
← Latest News
PR Newswire·

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

  • NewcelX Ltd. (NASDAQ: NCEL) announced that Professor Tamir Ben-Hur, MD, PhD, a renowned neurologist and former scientific advisor for Kadimastem Ltd., has joined its Scientific Advisory Board.
  • Prof. Ben-Hur serves as a Professor of Neurology at Hadassah University Medical Center & the Hebrew University of Jerusalem, with global expertise in neuroimmunology & stem-cell-based regenerative medicine.
  • Prof. Ben-Hur stated that combining cell therapy with central nervous system drug innovation will enable NewcelX to deliver meaningful therapeutic advances for patients worldwide.
  • Prof. Michel Revel, Chief Scientific Officer of NewcelX, noted that Prof. Ben-Hur brings deep clinical expertise & a shared commitment to advancing innovative cell therapies targeting the root causes of neurodegenerative disease.
  • Ronen Twito, Executive Chairman & CEO of NewcelX, confirmed that Prof. Ben-Hur's appointment reflects confidence in the company's science & mission to develop breakthrough therapies for ALS & diabetes.
  • This appointment serves as a strong endorsement of the merger uniting Kadimastem Ltd.'s advanced stem-cell platforms & clinical programs with NLS Pharmaceutic Ltd.'s expertise in central nervous system therapeutics.
  • NewcelX is a Zurich-headquartered biotechnology company developing cell-based & small-molecule therapies for neurodegenerative & metabolic diseases, with R&D operations in Ness Ziona, Israel.
  • The press release includes forward-looking statements regarding anticipated contributions, R&D impacts, & potential advancements following the merger, subject to risks such as clinical delays, regulatory approval uncertainties, & competitive pressures.